Given the potential associations between some drugs, such as statins, and angiogenesis [59], future studies assessing the interactions between commonly prescribed drugs and ANGPTL4, ANGPTL3, and endostatin would be helpful to further determine the potential value of these biomarkers for cardiovascular prognosis in patients with PAD. This evidence concerns the gene ANGPTL3 and peripheral arterial disease.